Public Drug Program Formulary Tables – Psoriasis and Psoriatic Arthritis

ProvinceClassGeneric NameDrug NamePsoriasisPsoriatic Arthritis
British ColumbiaBiologics and BiosimilarsEtanerceptEnbrel®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. Note: all requests for etanercept for patients weighing 63 kg or more will be assessed for
coverage with an etanercept biosimilar. Enbrel will be approved for new etanercept starts for pediatric patients weighing less than 63 kg.
No 
SaskatchewanBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation Yes – EDS. New psoriasis and psoriatic arthritis patients (i.e., patients without previous EDS approval for Enbrel) will be eligible only for a listed biosimilar formulation 
ManitobaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis. Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
OntarioBiologics and BiosimilarsEtanerceptEnbrel®Yes – L/UNo 
QuebecBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsEtanerceptEnbrel®No All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Enbrel must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsEtanerceptEnbrel®Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.  
Prince Edward IslandBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptEnbrel®Yes – S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. Yes –S/A. All new S/A requests for coverage of etanercept received after September 9, 2020, will be approved for the biosimilar version only. 
NunavutBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptEnbrel®NoYes – L/U
YukonBiologics and BiosimilarsEtanerceptEnbrel®Yes - EDS ; all new etanercept patients will be covered for Brenzys or ErelziYes – EDS; all new etanercept patients will be covered for Erelzi 
NIHBBiologics and BiosimilarsEtanerceptEnbrel®NoYes- L/U; for moderate to severe psoriatic arthritis. Coverage >1 year depends on response criteria.
British ColumbiaBiologics and BiosimilarsEtanerceptErelzi™Yes - S/A Yes – S/A
AlbertaBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsEtanerceptErelzi™Yes – EDS  Yes – EDS
OntarioBiologics and BiosimilarsEtanerceptErelzi™Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptErelzi™Yes – S/AYes – S/A 
New BrunswickBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptErelzi™NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptErelzi™Yes – S/A Yes – S/A
NunavutBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes – L/U
YukonBiologics and BiosimilarsEtanerceptErelzi™NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptErelzi™Yes- L/UYes- L/U
British ColumbiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes – S/A
AlbertaBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsEtanerceptBrenzys®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsEtanerceptBrenzys®Yes – L/U Yes – L/U
QuebecBiologics and BiosimilarsEtanerceptBrenzys®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsEtanerceptBrenzys®Yes - S/A Yes - S/A
Nova ScotiaBiologics and BiosimilarsEtanerceptBrenzys®Yes - EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Newfoundland and LabradorBiologics and BiosimilarsEtanerceptBrenzys®NoNo
NunavutBiologics and BiosimilarsEtanerceptBrenzys®NoNo
Northwest TerritoriesBiologics and BiosimilarsEtanerceptBrenzys®NoNo
YukonBiologics and BiosimilarsEtanerceptBrenzys®NoYes – EDS
NIHBBiologics and BiosimilarsEtanerceptBrenzys®NoNo
British ColumbiaBiologics and BiosimilarsAdalimumabHumira®No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.  
AlbertaBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.Yes - S/A. Patients must switch to the biosimilar version by May 1, 2022.
SaskatchewanBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab. Yes - EDS. Effective June 1, 2021, all listed Humira indications have a biosimilar adalimumab option. As such, new patients (i.e., patients without previous EDS approval for Humira) will be eligible only for a listed biosimilar formulation of adalimumab.
ManitobaBiologics and BiosimilarsAdalimumabHumira®Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis. Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
OntarioBiologics and BiosimilarsAdalimumabHumira®Yes - L/UNo
QuebecBiologics and BiosimilarsAdalimumabHumira®Yes - S/A. If treatment began before August 19, 2020.Yes - S/A. If treatment began before August 19, 2020.
New BrunswickBiologics and BiosimilarsAdalimumabHumira®No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Humira must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
Prince Edward IslandBiologics and BiosimilarsAdalimumabHumira®Yes - S/AYes - S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHumira®Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
NunavutBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHumira®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHumira®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsAdalimumabHumira®Yes- L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
AlbertaBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHadlima®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHadlima®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHadlima®Yes - S/A Yes - S/A
New BrunswickBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHadlima®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHadlima®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHadlima®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHadlima®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHyrimoz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHyrimoz®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHyrimoz®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHyrimoz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHyrimoz®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHyrimoz®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabIdacio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabIdacio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabIdacio®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabIdacio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabIdacio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabIdacio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabAmgevita®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabAmgevita®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabAmgevita®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabAmgevita®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabAmgevita®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabAmgevita®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
SaskatchewanBiologics and BiosimilarsAdalimumabHulio®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsAdalimumabHulio®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
QuebecBiologics and BiosimilarsAdalimumabHulio®Yes – S/A Yes – S/A
New BrunswickBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsAdalimumabHulio®NoNo
Prince Edward IslandBiologics and BiosimilarsAdalimumabHulio®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsAdalimumabHulio®Yes - S/AYes - S/A
NunavutBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsAdalimumabHulio®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabRemicade®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsInfliximabRemicade®NoNo 
SaskatchewanBiologics and BiosimilarsInfliximabRemicade®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRemicade®Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
OntarioBiologics and BiosimilarsInfliximabRemicade®No. May be covered through EAP in specific clinical circumstances .No. May be covered through EAP in specific clinical circumstances .
QuebecBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. If treatment began before August 19, 2020 Yes – S/A. If treatment began before August 19, 2020 
New BrunswickBiologics and BiosimilarsInfliximabRemicade®No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.No. All new S/A requests will be approved for biosimilar versions only. Patients on Remicade must switch to the biosimilar version by November 30, 2021.
Nova ScotiaBiologics and BiosimilarsInfliximabRemicade®Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved. 
Prince Edward IslandBiologics and BiosimilarsInfliximabRemicade®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemicade®Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016). No
NunavutBiologics and BiosimilarsInfliximabRemicade®NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemicade®NoNo
YukonBiologics and BiosimilarsInfliximabRemicade®Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
NIHBBiologics and BiosimilarsInfliximabRemicade®NoNo
British ColumbiaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabAvsola®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabAvsola®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabAvsola®Yes - EDSYes - EDS
OntarioBiologics and BiosimilarsInfliximabAvsola®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabAvsola®NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabAvsola®NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabAvsola®Yes - S/AYes - SA
NunavutBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabAvsola®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabInflectra®Yes – EDS Yes – EDS
OntarioBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabInflectra®Yes - S/A Yes - S/A
New BrunswickBiologics and BiosimilarsInfliximabInflectra®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabInflectra®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabInflectra®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabInflectra®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsInfliximabInflectra®Yes - EDSYes - EDS
NIHBBiologics and BiosimilarsInfliximabInflectra®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
AlbertaBiologics and BiosimilarsInfliximabOmvyence™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabOmvyence™NoNo
ManitobaBiologics and BiosimilarsInfliximabOmvyence™NoNo
OntarioBiologics and BiosimilarsInfliximabOmvyence™NoNo
QuebecBiologics and BiosimilarsInfliximabOmvyence™NoNo
New BrunswickBiologics and BiosimilarsInfliximabOmvyence™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabOmvyence™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabOmvyence™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabOmvyence™NoNo
NunavutBiologics and BiosimilarsInfliximabOmvyence™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabOmvyence™NoNo
YukonBiologics and BiosimilarsInfliximabOmvyence™NoNo
NIHBBiologics and BiosimilarsInfliximabOmvyence™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRemsima™NoNo
AlbertaBiologics and BiosimilarsInfliximabRemsima™NoNo
SaskatchewanBiologics and BiosimilarsInfliximabRemsima™NoNo
ManitobaBiologics and BiosimilarsInfliximabRemsima™NoNo
OntarioBiologics and BiosimilarsInfliximabRemsima™NoNo
QuebecBiologics and BiosimilarsInfliximabRemsima™NoNo
New BrunswickBiologics and BiosimilarsInfliximabRemsima™NoNo
Nova ScotiaBiologics and BiosimilarsInfliximabRemsima™NoNo
Prince Edward IslandBiologics and BiosimilarsInfliximabRemsima™NoNo
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRemsima™NoNo
NunavutBiologics and BiosimilarsInfliximabRemsima™NoNo
Northwest TerritoriesBiologics and BiosimilarsInfliximabRemsima™NoNo
YukonBiologics and BiosimilarsInfliximabRemsima™NoNo
NIHBBiologics and BiosimilarsInfliximabRemsima™No records available on NIHB websiteNo records available on NIHB website
British ColumbiaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
ManitobaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDS Yes – EDS
OntarioBiologics and BiosimilarsInfliximabRenflexis®Yes – L/UYes – L/U
QuebecBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
New BrunswickBiologics and BiosimilarsInfliximabRenflexis®Yes - S/AYes - S/A
Nova ScotiaBiologics and BiosimilarsInfliximabRenflexis®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsInfliximabRenflexis®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
Northwest TerritoriesBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
YukonBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
NIHBBiologics and BiosimilarsInfliximabRenflexis®Yes - L/UYes - L/U
British ColumbiaBiologics and BiosimilarsCertolizumab pegol Cimzia®Yes - L/UYes - L/U
AlbertaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
SaskatchewanBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
ManitobaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
OntarioBiologics and BiosimilarsCertolizumab pegol Cimzia®No – may be covered through EAP in specific clinical circumstancesNo – may be covered through EAP in specific clinical circumstances 
QuebecBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
New BrunswickBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
Nova ScotiaBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – S/A
NunavutBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – L/U
Northwest TerritoriesBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – L/U
YukonBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – EDS
NIHBBiologics and BiosimilarsCertolizumab pegol Cimzia®NoYes – L/U
AlbertaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
SaskatchewanBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
ManitobaBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
OntarioBiologics and BiosimilarsGolimumabSimponi®N/ANo – EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
New BrunswickBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
Nova ScotiaBiologics and BiosimilarsGolimumabSimponi®NoYes – EDS
Prince Edward IslandBiologics and BiosimilarsGolimumabSimponi®NoYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
NunavutBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
Northwest TerritoriesBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
YukonBiologics and BiosimilarsGolimumabSimponi®N/AYes – EDS
NIHBBiologics and BiosimilarsGolimumabSimponi®N/AYes – L/U
British ColumbiaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/A Yes – S/A
AlbertaBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UNo 
QuebecBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsIxekizumabTaltz®Yes – EDSYes – EDS
Prince Edward IslandBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsIxekizumabTaltz®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsIxekizumabTaltz®NoNo
NIHBBiologics and BiosimilarsIxekizumabTaltz®Yes – L/UYes – L/U
British ColumbiaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
AlbertaBiologics and BiosimilarsBrodalumabSiliq™NoN/A
SaskatchewanBiologics and BiosimilarsBrodalumabSiliq™Yes – EDS No
ManitobaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
OntarioBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
QuebecBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsBrodalumabSiliq™Yes – EDSN/A
Prince Edward IslandBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
Newfoundland and LabradorBiologics and BiosimilarsBrodalumabSiliq™Yes – S/AN/A
NunavutBiologics and BiosimilarsBrodalumabSiliq™Yes – L/Us.o.
Northwest TerritoriesBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
YukonBiologics and BiosimilarsBrodalumabSiliq™NoN/A
NIHBBiologics and BiosimilarsBrodalumabSiliq™Yes – L/UN/A
British ColumbiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
AlbertaBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
SaskatchewanBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
OntarioBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UNo 
QuebecBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Nova ScotiaBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDS Yes - EDS
Prince Edward IslandBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
Newfoundland and LabradorBiologics and BiosimilarsSecukinumabCosentyx®Yes – S/AYes – S/A
NunavutBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
Northwest TerritoriesBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
YukonBiologics and BiosimilarsSecukinumabCosentyx®Yes – EDSYes – EDS
NIHBBiologics and BiosimilarsSecukinumabCosentyx®Yes – L/UYes – L/U
British ColumbiaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
AlbertaBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
SaskatchewanBiologics and BiosimilarsUstekinumabStelara®Yes – EDSYes – EDS
ManitobaBiologics and BiosimilarsUstekinumabStelara®Yes – EDS No
OntarioBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
QuebecBiologics and BiosimilarsUstekinumabStelara®Yes – S/AYes – S/A
New BrunswickBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Nova ScotiaBiologics and BiosimilarsUstekinumabStelara®Yes - EDS No
Prince Edward IslandBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
Newfoundland and LabradorBiologics and BiosimilarsUstekinumabStelara®Yes – S/ANo
NunavutBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
Northwest TerritoriesBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
YukonBiologics and BiosimilarsUstekinumabStelara®Yes – EDS No
NIHBBiologics and BiosimilarsUstekinumabStelara®Yes – L/UNo
British ColumbiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
AlbertaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
SaskatchewanBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSNo
ManitobaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
OntarioBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
QuebecBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
New BrunswickBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
Nova ScotiaBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDS N/A
Prince Edward IslandBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/A N/A
Newfoundland and LabradorBiologics and BiosimilarsRisankizumabSkyrizi™Yes – S/AN/A
NunavutBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
Northwest TerritoriesBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
YukonBiologics and BiosimilarsRisankizumabSkyrizi™Yes – EDSN/A
NIHBBiologics and BiosimilarsRisankizumabSkyrizi™Yes – L/UN/A
British ColumbiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
AlbertaBiologics and BiosimilarsGuselkumabTremfya®NoNo
SaskatchewanBiologics and BiosimilarsGuselkumabTremfya®NoNo
ManitobaBiologics and BiosimilarsGuselkumabTremfya®NoNo
OntarioBiologics and BiosimilarsGuselkumabTremfya®NoNo
QuebecBiologics and BiosimilarsGuselkumabTremfya®NoNo
New BrunswickBiologics and BiosimilarsGuselkumabTremfya®NoNo
Nova ScotiaBiologics and BiosimilarsGuselkumabTremfya®NoNo
Prince Edward IslandBiologics and BiosimilarsGuselkumabTremfya®NoNo
Newfoundland and LabradorBiologics and BiosimilarsGuselkumabTremfya®NoNo
NunavutBiologics and BiosimilarsGuselkumabTremfya®NoNo
Northwest TerritoriesBiologics and BiosimilarsGuselkumabTremfya®NoNo
YukonBiologics and BiosimilarsGuselkumabTremfya®NoNo
NIHBBiologics and BiosimilarsGuselkumabTremfya®NoNo
British ColumbiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
AlbertaBiologics and BiosimilarsTildrakizumabIlumya™Yes - SAN/A
SaskatchewanBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
ManitobaBiologics and BiosimilarsTildrakizumabIlumya™Yes - EDS N/A
OntarioBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
QuebecBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
New BrunswickBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Nova ScotiaBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Prince Edward IslandBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Newfoundland and LabradorBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NunavutBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
Northwest TerritoriesBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
YukonBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
NIHBBiologics and BiosimilarsTildrakizumabIlumya™NoN/A
British ColumbiaBiologics and BiosimilarsAbataceptOrencia®NoNo
AlbertaBiologics and BiosimilarsAbataceptOrencia®NoNo
SaskatchewanBiologics and BiosimilarsAbataceptOrencia®NoNo
ManitobaBiologics and BiosimilarsAbataceptOrencia®NoNo
OntarioBiologics and BiosimilarsAbataceptOrencia®N/ANo. EAP may cover in specific clinical circumstances. 
QuebecBiologics and BiosimilarsAbataceptOrencia®NoNo
New BrunswickBiologics and BiosimilarsAbataceptOrencia®NoNo
Nova ScotiaBiologics and BiosimilarsAbataceptOrencia®NoNo
Prince Edward IslandBiologics and BiosimilarsAbataceptOrencia®NoNo
Newfoundland and LabradorBiologics and BiosimilarsAbataceptOrencia®NoNo
NunavutBiologics and BiosimilarsAbataceptOrencia®NoNo
Northwest TerritoriesBiologics and BiosimilarsAbataceptOrencia®NoNo
YukonBiologics and BiosimilarsAbataceptOrencia®NoNo
NIHBBiologics and BiosimilarsAbataceptOrencia®NoNo
British ColumbiaBiologics and BiosimilarsGolimumabSimponi®N/AYes – S/A
British ColumbiaSystemic Drugs MethotrexateYesYes
AlbertaSystemic Drugs MethotrexateYesYes
SaskatchewanSystemic Drugs MethotrexateYesYes
ManitobaSystemic Drugs CyclosporineMethotrexateYesN/A
OntarioSystemic Drugs MethotrexateYesYes
QuebecSystemic Drugs MethotrexateYesYes
New BrunswickSystemic Drugs MethotrexateYesYes
Nova ScotiaSystemic Drugs MethotrexateYesYes
Prince Edward IslandSystemic Drugs MethotrexateYesYes
Newfoundland and LabradorSystemic Drugs MethotrexateYesYes
NunavutSystemic Drugs MethotrexateYesYes
Northwest TerritoriesSystemic Drugs MethotrexateYesYes
YukonSystemic Drugs MethotrexateYesYes
NIHBSystemic Drugs MethotrexateYesYes
British ColumbiaSystemic Drugs CyclosporineYes – S/AN/A
AlbertaSystemic Drugs CyclosporineYes – S/AN/A
SaskatchewanSystemic Drugs Yes – EDS N/A
ManitobaSystemic Drugs CyclosporineYes – EDS N/A
OntarioSystemic Drugs CyclosporineYes – L/UN/A
QuebecSystemic Drugs CyclosporineYesN/A
New BrunswickSystemic Drugs CyclosporineYesN/A
Nova ScotiaSystemic Drugs CyclosporineYesN/A
Prince Edward IslandSystemic Drugs CyclosporineYesN/A
Newfoundland and LabradorSystemic Drugs CyclosporineYesN/A
NunavutSystemic Drugs CyclosporineYesN/A
Northwest TerritoriesSystemic Drugs CyclosporineYesN/A
YukonSystemic Drugs CyclosporineYesN/A
NIHBSystemic Drugs CyclosporineYesN/A
British ColumbiaSystemic Drugs AcitretinSoriatane®YesN/A
AlbertaSystemic Drugs AcitretinSoriatane®YesN/A
SaskatchewanSystemic Drugs AcitretinSoriatane®Yes – EDS N/A
ManitobaSystemic Drugs AcitretinSoriatane®YesN/A
OntarioSystemic Drugs AcitretinSoriatane®YesN/A
QuebecSystemic Drugs AcitretinSoriatane®YesN/A
New BrunswickSystemic Drugs AcitretinSoriatane®YesN/A
Nova ScotiaSystemic Drugs AcitretinSoriatane®YesN/A
Prince Edward IslandSystemic Drugs AcitretinSoriatane®Yes-SAN/A
Newfoundland and LabradorSystemic Drugs AcitretinSoriatane®YesN/A
NunavutSystemic Drugs AcitretinSoriatane®YesN/A
Northwest TerritoriesSystemic Drugs AcitretinSoriatane®YesN/A
YukonSystemic Drugs AcitretinSoriatane®Yes – EDS N/A
NIHBSystemic Drugs AcitretinSoriatane®YesN/A
British ColumbiaSystemic Drugs ApremilastOtezla®NoNo
AlbertaSystemic Drugs ApremilastOtezla®NoNo
SaskatchewanSystemic Drugs ApremilastOtezla®NoNo
ManitobaSystemic Drugs ApremilastOtezla®NoNo
OntarioSystemic Drugs ApremilastOtezla®NoNo
QuebecSystemic Drugs ApremilastOtezla®Yes – S/ANo
New BrunswickSystemic Drugs ApremilastOtezla®NoNo
Nova ScotiaSystemic Drugs ApremilastOtezla®NoNo
Prince Edward IslandSystemic Drugs ApremilastOtezla®NoNo
Newfoundland and LabradorSystemic Drugs ApremilastOtezla®NoNo
NunavutSystemic Drugs ApremilastOtezla®NoNo
Northwest TerritoriesSystemic Drugs ApremilastOtezla®NoNo
YukonSystemic Drugs ApremilastOtezla®NoNo
NIHBSystemic Drugs ApremilastOtezla®NoNo 
British ColumbiaSystemic Drugs LeflunomideArava®NoNo 
AlbertaSystemic Drugs LeflunomideArava®NoNo
SaskatchewanSystemic Drugs LeflunomideArava®NoYes – EDS
ManitobaSystemic Drugs LeflunomideArava®NoNo
OntarioSystemic Drugs LeflunomideArava®YesYes
QuebecSystemic Drugs LeflunomideArava®N/AYes
New BrunswickSystemic Drugs LeflunomideArava®N/AYes
Nova ScotiaSystemic Drugs LeflunomideArava®N/AYes
Prince Edward IslandSystemic Drugs LeflunomideArava®N/AYes
Newfoundland and LabradorSystemic Drugs LeflunomideArava®N/AYes
NunavutSystemic Drugs LeflunomideArava®N/AYes
Northwest TerritoriesSystemic Drugs LeflunomideArava®N/AYes
YukonSystemic Drugs LeflunomideArava®NoNo
NIHBSystemic Drugs LeflunomideArava®YesYes
British ColumbiaSystemic Drugs SulfasalazineYesYes
AlbertaSystemic Drugs SulfasalazineYesYes
SaskatchewanSystemic Drugs SulfasalazineN/AYes
ManitobaSystemic Drugs SulfasalazineYesYes
OntarioSystemic Drugs SulfasalazineN/AYes
QuebecSystemic Drugs SulfasalazineN/AYes
New BrunswickSystemic Drugs SulfasalazineN/AYes
Nova ScotiaSystemic Drugs SulfasalazineN/AYes
Prince Edward IslandSystemic Drugs SulfasalazineN/AYes
Newfoundland and LabradorSystemic Drugs SulfasalazineN/AYes
NunavutSystemic Drugs SulfasalazineN/AYes
Northwest TerritoriesSystemic Drugs SulfasalazineN/AYes
YukonSystemic Drugs SulfasalazineN/ANo
NIHBSystemic Drugs SulfasalazineYesYes
British ColumbiaSystemic Drugs CelecoxibNoYes – S/A
AlbertaSystemic Drugs CelecoxibNoNo
SaskatchewanSystemic Drugs CelecoxibYesYes
ManitobaSystemic Drugs CelecoxibYesYes
OntarioSystemic Drugs CelecoxibN/ANo
QuebecSystemic Drugs CelecoxibN/AYes
New BrunswickSystemic Drugs CelecoxibN/AYes
Nova ScotiaSystemic Drugs CelecoxibN/ANo
Prince Edward IslandSystemic Drugs CelecoxibN/AYes
Newfoundland and LabradorSystemic Drugs CelecoxibN/AYes
NunavutSystemic Drugs CelecoxibN/AYes
Northwest TerritoriesSystemic Drugs CelecoxibN/AYes
YukonSystemic Drugs CelecoxibN/AYes
NIHBSystemic Drugs CelecoxibYesYes
British ColumbiaSystemic Drugs TofacitinibXeljanz®N/ANo
AlbertaSystemic Drugs TofacitinibXeljanz®N/ANo
SaskatchewanSystemic Drugs TofacitinibXeljanz®N/ANo
ManitobaSystemic Drugs TofacitinibXeljanz®N/ANo
OntarioSystemic Drugs TofacitinibXeljanz®N/ANo
QuebecSystemic Drugs TofacitinibXeljanz®N/ANo
New BrunswickSystemic Drugs TofacitinibXeljanz®N/ANo
Nova ScotiaSystemic Drugs TofacitinibXeljanz®N/ANo
Prince Edward IslandSystemic Drugs TofacitinibXeljanz®NoNo
Newfoundland and LabradorSystemic Drugs TofacitinibXeljanz®N/ANo
NunavutSystemic Drugs TofacitinibXeljanz®NoNo
Northwest TerritoriesSystemic Drugs TofacitinibXeljanz®NoNo
YukonSystemic Drugs TofacitinibXeljanz®NoNo
NIHBSystemic Drugs TofacitinibXeljanz®N/ANo
British ColumbiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
AlbertaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
SaskatchewanPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesYes
ManitobaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
OntarioPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes – L/UN/A
QuebecPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
New BrunswickPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Nova ScotiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®Yes - EDSN/A
Prince Edward IslandPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Newfoundland and LabradorPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NunavutPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
Northwest TerritoriesPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
YukonPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
NIHBPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcipotriol - Dovonex®YesN/A
British ColumbiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
AlbertaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
SaskatchewanPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoNo
ManitobaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
OntarioPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®Yes – L/UN/A
QuebecPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
New BrunswickPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Nova ScotiaPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
Prince Edward IslandPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
Newfoundland and LabradorPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®NoN/A
NunavutPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®Yes N/A
Northwest TerritoriesPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
YukonPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®Yes N/A
NIHBPrescription Topical Treatments Vitamin_D3_Analogues(Dovonex® Silkis®)Calcitriol - Silkis®YesN/A
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesYes
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDS N/A
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – in specific clinical situationsN/A
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – EDS N/A
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes N/A
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYes – S/AN/A
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_GelYesN/A
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesYes
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – in specific clinical situationsN/A
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes – S/AN/A
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYes N/A
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentNoN/A
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsDovobet®_OintmentYesN/A
British ColumbiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamNoN/A
AlbertaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
SaskatchewanPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesYes
ManitobaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
OntarioPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – in specific clinical situationsN/A
QuebecPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – S/AN/A
New BrunswickPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Nova ScotiaPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes – EDS N/A
Prince Edward IslandPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
Newfoundland and LabradorPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NunavutPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
Northwest TerritoriesPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
YukonPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYesN/A
NIHBPrescription Topical Treatments Combination Vitamin D3 Analogues and CorticosteroidsEnstilar™_FoamYes N/A
British ColumbiaPrescription Topical Treatments Topical RetinoidsTazaroteneYesN/A
AlbertaPrescription Topical Treatments Topical RetinoidsTazaroteneYesN/A
SaskatchewanPrescription Topical Treatments Topical RetinoidsTazaroteneYesYes
ManitobaPrescription Topical Treatments Topical RetinoidsTazaroteneNoN/A
OntarioPrescription Topical Treatments Topical RetinoidsTazaroteneNoN/A
QuebecPrescription Topical Treatments Topical RetinoidsTazaroteneNoN/A
New BrunswickPrescription Topical Treatments Topical RetinoidsTazaroteneYes – S/AN/A
Nova ScotiaPrescription Topical Treatments Topical RetinoidsTazaroteneYes – EDSN/A
Prince Edward IslandPrescription Topical Treatments Topical RetinoidsTazaroteneNoN/A
Newfoundland and LabradorPrescription Topical Treatments Topical RetinoidsTazaroteneYes – S/AN/A
NunavutPrescription Topical Treatments Topical RetinoidsTazaroteneYesN/A
Northwest TerritoriesPrescription Topical Treatments Topical RetinoidsTazaroteneYesN/A
YukonPrescription Topical Treatments Topical RetinoidsTazaroteneYesN/A
NIHBPrescription Topical Treatments Topical RetinoidsTazaroteneYesYes
British ColumbiaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
AlbertaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®Yes - SAN/A
SaskatchewanPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoNo
ManitobaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A
OntarioPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
QuebecPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
New BrunswickPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
Nova ScotiaPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
Prince Edward IslandPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
Newfoundland and LabradorPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
NunavutPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
Northwest TerritoriesPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
YukonPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®NoN/A
NIHBPrescription Topical Treatments Halobetasol propionate and tazaroteneDUOBRII®YesN/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.